Who
Mary Ann Gray
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics; Director, RAPT Therapeutics; Director, Compass Therapeutics; Director, BioAtla; Director, Palisade Bio; Director, Sarepta Therapeutics; Director, Senomyx; Director, Juniper Pharmaceuticals.
In numbers
- Trades disclosed
- 192
- Buys
- 3
- Sells
- 3
- Bought
- $48K
- Sold
- $848K
- Companies
- 14
- Companies where not an officer
- 14
- First trade
- 17 May 2006
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT TherapeuticsBiotechnology | SEC FORM 4 Code U | —4,956 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,618 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,072 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,561 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,650 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,229 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,813 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —498 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,813 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —498 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —938 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —478 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —938 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —484 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,063 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —560 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Mary Ann Gray; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.